<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="screen candidate drugs against the novel coronavirus (later termed severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)) and inhibit excessive immune"/>
 <result pre="candidate drugs against the novel coronavirus (later termed severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)) and inhibit excessive immune response."/>
 <result pre="drugs against the novel coronavirus (later termed severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)) and inhibit excessive immune response. Related"/>
 <result pre="research and development Introduction An outbreak of a series of" exact="pneumonia" post="cases associated with a novel coronavirus has been reported"/>
 <result pre="patients developed mild symptoms of dry cough, dyspnea, fever, and" exact="bilateral" post="lung infiltrates on imaging [11â€&quot;13]. Besides, numbers of researches"/>
 <result pre="[14]. There are six strains of coronaviruses that are confirmed" exact="infectious" post="to humans, which are named for their coronary appearance"/>
 <result pre="a kind of highly pathogenic coronavirus that could cause severe" exact="respiratory" post="illness and even death [16]. However, SARS-CoV-2 has higher"/>
 <result pre="from human to human comparatively, which makes humans vulnerable to" exact="infection" post="and makes it harder to get this outbreak under"/>
 <result pre="worse, the control of COVID-19 presents multiple challenges in the" exact="short" post="term [20]. Nevertheless, no specific antiviral medicine is available"/>
 <result pre="Qi and Ying patterns), and critical case (internal blockage and" exact="external" post="desertion pattern) followed by a rehabilitation stage (lung and"/>
 <result pre="pattern) followed by a rehabilitation stage (lung and spleen qi" exact="deficiency" post="patterns or deficiency of both qi and yin patterns)."/>
 <result pre="a rehabilitation stage (lung and spleen qi deficiency patterns or" exact="deficiency" post="of both qi and yin patterns). Depending on the"/>
 <result pre="were used at different stages [30, 34]. At present, a" exact="total" post="of 23 different Chinese medicines are recommended nationwide for"/>
 <result pre="headache, sore body, sore throat, cough, bad wind or cold," exact="runny nose," post="red tongue, thin yellow fur Huoxiangzhengqi capsule (pill, oral"/>
 <result pre="Aversion to cold without sweat, headache body weight, limb pain," exact="chest" post="Diaphragm full, thirst not to drink, loose stools, drowning"/>
 <result pre="huo-xiang, da-huang, hong-jing-tian, bao-he, gan-cao Medical observation periodâ€&quot;clinical manifestation 2" exact="Fever" post="or high fever, chills, muscle soreness, stuffy nose, runny"/>
 <result pre="Medical observation periodâ€&quot;clinical manifestation 2 Fever or high fever, chills," exact="muscle" post="soreness, stuffy nose, runny nose, cough, headache, dry throat,"/>
 <result pre="2 Fever or high fever, chills, muscle soreness, stuffy nose," exact="runny nose," post="cough, headache, dry throat, sore throat, red tongue, yellow,"/>
 <result pre="periodâ€&quot;clinical manifestation Fever, bad wind, sore throat, headache, stuffy nose," exact="runny nose," post="cough, red tip of tongue, thin white dry or"/>
 <result pre="tongue coating, floating pulse Xiyanping injection Chuan-xin-lian Clinical treatment periodâ€&quot;severe" exact="Severe" post="fever and polydipsia, dyspnea and anhelation, delirium, blurred vision,"/>
 <result pre="rash, or hematemesis and epistaxis, or convulsion of the limbs." exact="Tongue" post="with little or no fur, deep and count pulse,"/>
 <result pre="Hong-hua, chi-shao, chuan-xiong, dan-shen, dang-gui Clinical treatment periodâ€&quot;severe and critical" exact="Severe" post="fever and polydipsia, dyspnea and anhelation, delirium, blurred vision,"/>
 <result pre="rash, or hematemesis and epistaxis, or convulsion of the limbs." exact="Tongue" post="with little or no fur, deep and count pulse,"/>
 <result pre="Reduning injection Qing-hao, jin-yin-hua, zhi-zi Clinical treatment periodâ€&quot;severe and critical" exact="Severe" post="fever and polydipsia, dyspnea and anhelation, delirium, blurred vision,"/>
 <result pre="rash, or hematemesis and epistaxis, or convulsion of the limbs." exact="Tongue" post="with little or no fur, deep and count pulse,"/>
 <result pre="rapid pulse Shenfu injection Hong-shen, fu-zi Clinical treatment periodâ€&quot;critical Dyspnea," exact="asthma" post="requires assisted ventilation, dizziness, irritability, cold sweaty limbs, purple"/>
 <result pre="pulse. Shengmai injection Hong-shen, mai-dong, wu-wei-zi Clinical treatment periodâ€&quot;critical Dyspnea," exact="asthma" post="requires assisted ventilation, dizziness, irritability, cold sweaty limbs, purple"/>
 <result pre="away heat, detoxifying, calming and resuscitating, fever, pathogen into pericardium," exact="febrile convulsion," post="delirium, red or crimson tongue, powerful pulse number; apoplexy"/>
 <result pre="crimson tongue, powerful pulse number; apoplexy coma and encephalitis, meningitis," exact="toxic encephalopathy," post="cerebral hemorrhage, septicemia Xiangshaliujun-wan Ban-xia, chen-pi, mu-xiang, sha-ren, dang-shen,"/>
 <result pre="powerful pulse number; apoplexy coma and encephalitis, meningitis, toxic encephalopathy," exact="cerebral hemorrhage," post="septicemia Xiangshaliujun-wan Ban-xia, chen-pi, mu-xiang, sha-ren, dang-shen, bai-zhu, fu-ling,"/>
 <result pre="period 3 Invigorate the spleen and stomach. Used for spleen" exact="deficiency" post="and qi stagnation, indigestion, belching Shao, wan abdominal distension"/>
 <result pre="injection Huang-qin, xiong-dan, shan-yang-jiao,-jin-yin-hua, lian-qiao Clinical treatment periodâ€&quot;severe and critical" exact="Severe" post="fever and polydipsia, dyspnea and anhelation, delirium, blurred vision,"/>
 <result pre="rash, or hematemesis and epistaxis, or convulsion of the limbs." exact="Tongue" post="with little or no fur, deep and count pulse,"/>
 <result pre="injection She-xiang, bing-pian, zhi-zi, yu-jin Clinical treatment periodâ€&quot;severe and critical" exact="Severe" post="fever and polydipsia, dyspnea and anhelation, delirium, blurred vision,"/>
 <result pre="rash, or hematemesis and epistaxis, or convulsion of the limbs." exact="Tongue" post="with little or no fur, deep and count pulse,"/>
 <result pre="in 2001 [43, 44]. It is a type of human" exact="immunodeficiency" post="virus (HIV) protease inhibitor that can block the cleavage"/>
 <result pre="forms of HIV particles and prevent a new round of" exact="infection" post="[47]. Currently, in vitro studies have shown that lopinavir/ritonavir"/>
 <result pre="shown that lopinavir/ritonavir can inhibit the replication of Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus"/>
 <result pre="that lopinavir/ritonavir can inhibit the replication of Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV)"/>
 <result pre="replication of Middle East respiratory syndrome coronavirus (MERS-CoV) and severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) to exert antiviral effects [48]."/>
 <result pre="of Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) to exert antiviral effects [48]. Based"/>
 <result pre="Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) to exert antiviral effects [48]. Based on"/>
 <result pre="period of antiviral treatment to improve clinical symptoms and reduce" exact="viral" post="load. The oral dosage is recommended once a day"/>
 <result pre="not significantly accelerate clinical improvement, reduce mortality, or diminish throat" exact="viral" post="RNA detectability in patients with COVID-19 [50]. Besides, it"/>
 <result pre="Besides, it should be noted that lopinavir/ritonavir is an inhibitor" exact="of liver" post="P450 isoenzyme CYP3A. When it is combined with drugs"/>
 <result pre="and improve patientâ€™s condition, but the therapeutic process should be" exact="limited" post="to 10Â days [32]. Notably, patients with contraindications should"/>
 <result pre="effect of ribavirin in vitro showed that ribavirin could reduce" exact="viral infection" post="[55]. However, the effectiveness and safety of ribavirin for"/>
 <result pre="of ribavirin in vitro showed that ribavirin could reduce viral" exact="infection" post="[55]. However, the effectiveness and safety of ribavirin for"/>
 <result pre="exerts an antiviral effect by inhibiting the fusion of the" exact="viral" post="lipid membrane with the host cell to block the"/>
 <result pre="clinical trials have been officially launched in China that a" exact="total" post="of 761 patients are planned to be included in"/>
 <result pre="against almost all RNA viruses, such as West Nile virus," exact="yellow fever" post="virus, enterovirus, and Ebola virus [69â€&quot;72]. On February 15,"/>
 <result pre="the indication was approved for the treatment of new or" exact="recurrent" post="epidemics in adults. Thus, favipiravir became a potential drug"/>
 <result pre="in virus infected cells, thus blocking the formation of mature" exact="infectious" post="virus particles [76, 77]. Clinically, darunavir is mainly used"/>
 <result pre="HIV by inhibiting reverse transcriptase and can also effectively inhibit" exact="hepatitis" post="B virus (HBV) reverse transcription process [77, 80]. It"/>
 <result pre="Phosphate Chloroquine phosphate is mainly used in the treatment of" exact="malaria" post="and rheumatism in clinical [81â€&quot;83]. Numerous studies have presented"/>
 <result pre="has been found that chloroquine phosphate could effectively inhibit the" exact="infection" post="of coronavirus at the cellular level [85â€&quot;87]. It has"/>
 <result pre="antimalarial drug and has been used for the treatment of" exact="rheumatoid arthritis" post="and lupus erythematosus [89â€&quot;91]. Due to its antiviral activity,"/>
 <result pre="drug and has been used for the treatment of rheumatoid" exact="arthritis" post="and lupus erythematosus [89â€&quot;91]. Due to its antiviral activity,"/>
 <result pre="has been used for the treatment of rheumatoid arthritis and" exact="lupus erythematosus" post="[89â€&quot;91]. Due to its antiviral activity, hydroxychloroquine has also"/>
 <result pre="According to different binding receptors, it can be divided into" exact="type I," post="type II, and type III. Among them, type II"/>
 <result pre="different binding receptors, it can be divided into type I," exact="type II," post="and type III. Among them, type II IFN (mainly"/>
 <result pre="it can be divided into type I, type II, and" exact="type III." post="Among them, type II IFN (mainly Î±/Î² IFN) plays"/>
 <result pre="into type I, type II, and type III. Among them," exact="type II" post="IFN (mainly Î±/Î² IFN) plays an important role in"/>
 <result pre="Î±/Î² IFN) plays an important role in the control of" exact="virus infection." post="Naturally, IFN-Î± is a very important immune protective cytokine"/>
 <result pre="a very important immune protective cytokine in human response to" exact="virus infection" post="[100, 101]. It could induce the same cell to"/>
 <result pre="very important immune protective cytokine in human response to virus" exact="infection" post="[100, 101]. It could induce the same cell to"/>
 <result pre="activity of IL-6 receptor and achieving the goal of treating" exact="rheumatoid arthritis" post="[104â€&quot;106]. IL-6R plays an important role in the occurrence"/>
 <result pre="of IL-6 receptor and achieving the goal of treating rheumatoid" exact="arthritis" post="[104â€&quot;106]. IL-6R plays an important role in the occurrence"/>
 <result pre="role in the occurrence and development of some inflammatory and" exact="autoimmune diseases." post="As an activator of IL-6, sIL-6R can enhance the"/>
 <result pre="for severe cases with high inflammatory response or children with" exact="acute" post="respiratory distress syndrome [32, 112]. However, the side effects"/>
 <result pre="severe cases with high inflammatory response or children with acute" exact="respiratory" post="distress syndrome [32, 112]. However, the side effects of"/>
 <result pre="with high inflammatory response or children with acute respiratory distress" exact="syndrome" post="[32, 112]. However, the side effects of glucocorticoids are"/>
 <result pre="antibodies to treat COVID-19 has some obvious problems such as" exact="limited" post="sources of therapeutic plasma, different concentrations and activities of"/>
 <result pre="within the context of a well-designed clinical trial. In the" exact="absence of" post="vaccines and specific therapeutic drugs, the recovery plasma therapy"/>
 <result pre="Intravenous immunoglobulin in large doses could be used for severe" exact="systemic" post="inflammatory response syndrome [11]. It has been suggested that"/>
 <result pre="large doses could be used for severe systemic inflammatory response" exact="syndrome" post="[11]. It has been suggested that intestinal microecological regulator"/>
 <result pre="intestinal microecological regulator could maintain intestinal microecological balance and prevent" exact="secondary" post="bacterial infection [32]. Perspective As for a new emerging"/>
 <result pre="microecological regulator could maintain intestinal microecological balance and prevent secondary" exact="bacterial infection" post="[32]. Perspective As for a new emerging acute infectious"/>
 <result pre="regulator could maintain intestinal microecological balance and prevent secondary bacterial" exact="infection" post="[32]. Perspective As for a new emerging acute infectious"/>
 <result pre="secondary bacterial infection [32]. Perspective As for a new emerging" exact="acute" post="infectious disease caused by SARS-CoV-2, there are still no"/>
 <result pre="bacterial infection [32]. Perspective As for a new emerging acute" exact="infectious disease" post="caused by SARS-CoV-2, there are still no specific antiviral"/>
 <result pre="infection [32]. Perspective As for a new emerging acute infectious" exact="disease" post="caused by SARS-CoV-2, there are still no specific antiviral"/>
 <result pre="and treatment plans on COVID-19, which was formulated in a" exact="short" post="time by professionals in various fields. But it is"/>
 <result pre="and development of specific medicine and vaccine according to the" exact="infection" post="mechanism and characteristic structure of new crown virus. What"/>
 <result pre="it is easy to produce drug-resistant strains. Secondly, after the" exact="acute" post="infectious period of a novel coronavirus, the patient is"/>
 <result pre="is easy to produce drug-resistant strains. Secondly, after the acute" exact="infectious" post="period of a novel coronavirus, the patient is likely"/>
 <result pre="have developed a corresponding durable immunity. However, compared with the" exact="transient" post="infection of virus epidemic, the new drug development cycle"/>
 <result pre="developed a corresponding durable immunity. However, compared with the transient" exact="infection" post="of virus epidemic, the new drug development cycle is"/>
 <result pre="development departments are needed to achieve a breakthrough in a" exact="short" post="period of time, for accumulating experience of the possible"/>
 <result pre="the authors. References References 1.KsiazekTGErdmanDGoldsmithCSZakiSRPeretTEmerySTongSUrbaniCComerJALimWRollinPEDowellSFLingAEHumphreyCDShiehWJGuarnerJPaddockCDRotaPFieldsBDeRisiJYangJYCoxNHughesJMLeDucJWBelliniWJAndersonLJA novel coronavirus associated with severe" exact="acute" post="respiratory syndromeN Engl J Med2003348201953196612690092 2.LuHStrattonCWTangYWOutbreak of pneumonia of"/>
 <result pre="authors. References References 1.KsiazekTGErdmanDGoldsmithCSZakiSRPeretTEmerySTongSUrbaniCComerJALimWRollinPEDowellSFLingAEHumphreyCDShiehWJGuarnerJPaddockCDRotaPFieldsBDeRisiJYangJYCoxNHughesJMLeDucJWBelliniWJAndersonLJA novel coronavirus associated with severe acute" exact="respiratory" post="syndromeN Engl J Med2003348201953196612690092 2.LuHStrattonCWTangYWOutbreak of pneumonia of unknown"/>
 <result pre="with severe acute respiratory syndromeN Engl J Med2003348201953196612690092 2.LuHStrattonCWTangYWOutbreak of" exact="pneumonia" post="of unknown etiology in Wuhan, China: the mystery and"/>
 <result pre="the miracleJ Med Virol202092440140231950516 3.ZhuNZhangDWangWLiXYangBSongJZhaoXHuangBShiWLuRNiuPZhanFMaXWangDXuWWuGGaoGFTanWA novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med2020382872773331978945 4.BastolaASahRRodriguez-MoralesAJLalBKJhaROjhaHCShresthaBChuDKWPoonLLMCostelloAMoritaKPandeyBDThe first 2019"/>
 <result pre="novel coronavirus in the United StatesN Engl J Med20203821092993632004427 6.LivingstonEBucherKCoronavirus" exact="disease" post="2019 (COVID-19) in ItalyJama20203231335 7.LaiCCShihTPKoWCTangHJHsuehPRSevere acute respiratory syndrome coronavirus"/>
 <result pre="Engl J Med20203821092993632004427 6.LivingstonEBucherKCoronavirus disease 2019 (COVID-19) in ItalyJama20203231335 7.LaiCCShihTPKoWCTangHJHsuehPRSevere" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):"/>
 <result pre="J Med20203821092993632004427 6.LivingstonEBucherKCoronavirus disease 2019 (COVID-19) in ItalyJama20203231335 7.LaiCCShihTPKoWCTangHJHsuehPRSevere acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the"/>
 <result pre="Med20203821092993632004427 6.LivingstonEBucherKCoronavirus disease 2019 (COVID-19) in ItalyJama20203231335 7.LaiCCShihTPKoWCTangHJHsuehPRSevere acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic"/>
 <result pre="Antimicrob Agents202055310592432081636 8.GuoYRCaoQDHongZSTanYYChenSDJinHJTanKSWangDYYanYThe origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreak - an update on the statusMil"/>
 <result pre="Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, China. Jama 2020. 12.ChenNZhouMDongXQuJGongFHanYQiuYWangJLiuYWeiYXiaJYuTZhangXZhangLEpidemiological and clinical characteristics"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet20203951022350751332007143 13.Henry BM; Vikse"/>
 <result pre="J Med 2020, 382. 14.XuZShiLWangYZhangJHuangLZhangCLiuSZhaoPLiuHZhuLTaiYBaiCGaoTSongJXiaPDongJZhaoJWangFSPathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir Med2020842042232085846 15.YinYWunderinkRGMERS, SARS and other"/>
 <result pre="Med 2020, 382. 14.XuZShiLWangYZhangJHuangLZhangCLiuSZhaoPLiuHZhuLTaiYBaiCGaoTSongJXiaPDongJZhaoJWangFSPathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir Med2020842042232085846 15.YinYWunderinkRGMERS, SARS and other coronaviruses"/>
 <result pre="J Travel Med 2020, 27, (2). 17.ChanJFYuanSKokKHcollab: To, K. KChuHYangJXingFLiuJYipCCPoonRWTsoiHWLoSKChanKHPoonVKChanWMIpJDCaiJPChengVCChenHHuiCKYuenKYA" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="2020, 27, (2). 17.ChanJFYuanSKokKHcollab: To, K. KChuHYangJXingFLiuJYipCCPoonRWTsoiHWLoSKChanKHPoonVKChanWMIpJDCaiJPChengVCChenHHuiCKYuenKYA familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="severity and improve the prognosis of patients with novel coronavirus" exact="disease" post="(COVID-19). J Intern Med 2020. 28.MitjÃ OClotetBUse of antiviral"/>
 <result pre="Chinese medicine for COVID-19 treatmentPharmacol Res202015510474332145402 31.Guidance for corona virus" exact="disease" post="2019: prevention, control, diagnosis and management. 2020, (People's Medical"/>
 <result pre="Can Chinese medicine be used for prevention of corona virus" exact="disease" post="2019 (COVID-19)? A review of historical classics, research evidence"/>
 <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatmentBiosci Trends2020141646832037389 36.Runfeng"/>
 <result pre="Huangqin Decoction, a Chinese herbal formula, inhibits influenza a/PR/8/34 (H1N1)" exact="virus infection" post="in vitro and in vivo. Viruses 2018, 10, (3)."/>
 <result pre="Decoction, a Chinese herbal formula, inhibits influenza a/PR/8/34 (H1N1) virus" exact="infection" post="in vitro and in vivo. Viruses 2018, 10, (3)."/>
 <result pre="39.YinJMaLWangHYanHHuJJiangWLiYChinese herbal medicine compound Yi-Zhi-Hao pellet inhibits replication of influenza" exact="virus infection" post="through activation of heme oxygenase-1Acta Pharm Sin B20177663063729159022 40.ZouWWangJLiuYEffect"/>
 <result pre="herbal medicine compound Yi-Zhi-Hao pellet inhibits replication of influenza virus" exact="infection" post="through activation of heme oxygenase-1Acta Pharm Sin B20177663063729159022 40.ZouWWangJLiuYEffect"/>
 <result pre="Sin B20177663063729159022 40.ZouWWangJLiuYEffect of traditional Chinese medicine for treating human" exact="immunodeficiency" post="virus infections and acquired immune deficiency syndrome: boosting immune"/>
 <result pre="40.ZouWWangJLiuYEffect of traditional Chinese medicine for treating human immunodeficiency virus" exact="infections" post="and acquired immune deficiency syndrome: boosting immune and alleviating"/>
 <result pre="traditional Chinese medicine for treating human immunodeficiency virus infections and" exact="acquired" post="immune deficiency syndrome: boosting immune and alleviating symptomsChin J"/>
 <result pre="medicine for treating human immunodeficiency virus infections and acquired immune" exact="deficiency" post="syndrome: boosting immune and alleviating symptomsChin J Integr Med20162213826577109"/>
 <result pre="and research information on drug-induced liver injury, National Institute of" exact="Diabetes" post="and Digestive and Kidney Diseases: Bethesda (MD), 2012. 45.CanalsFMasiÃ¡MGutiÃ©rrezFDevelopments"/>
 <result pre="drug-induced liver injury, National Institute of Diabetes and Digestive and" exact="Kidney" post="Diseases: Bethesda (MD), 2012. 45.CanalsFMasiÃ¡MGutiÃ©rrezFDevelopments in early diagnosis and"/>
 <result pre="Bethesda (MD), 2012. 45.CanalsFMasiÃ¡MGutiÃ©rrezFDevelopments in early diagnosis and therapy of" exact="HIV infection" post="in newbornsExpert Opin Pharmacother2018191132528764578 46.Coelho AV; Tricarico PM; Celsi"/>
 <result pre="(MD), 2012. 45.CanalsFMasiÃ¡MGutiÃ©rrezFDevelopments in early diagnosis and therapy of HIV" exact="infection" post="in newbornsExpert Opin Pharmacother2018191132528764578 46.Coelho AV; Tricarico PM; Celsi"/>
 <result pre="Infect Dis20166381113112127439527 48.MoYFisherDA review of treatment modalities for Middle East" exact="respiratory" post="syndromeJ Antimicrob Chemother201671123340335027585965 49.Martinez MA, Compounds with therapeutic potential"/>
 <result pre="Antimicrob Chemother201671123340335027585965 49.Martinez MA, Compounds with therapeutic potential against novel" exact="respiratory" post="2019 coronavirus. Antimicrob Agents Chemother 2020, 64. 50.Cao, B.;"/>
 <result pre="N Engl J Med 2020. 51.JordanPCStevensSKDevalJNucleosides for the treatment of" exact="respiratory" post="RNA virus infectionsAntivir Chem Chemother201826204020661876448329562753 52.RabaanAAAlahmedSHBazziAMAlhaniHMA review of candidate"/>
 <result pre="Chem Chemother201826204020661876448329562753 52.RabaanAAAlahmedSHBazziAMAlhaniHMA review of candidate therapies for Middle East" exact="respiratory" post="syndrome from a molecular perspectiveJ Med Microbiol20176691261127428855003 53.Al-TawfiqJAMemishZAUpdate on"/>
 <result pre="Chemother201826204020661876448329562753 52.RabaanAAAlahmedSHBazziAMAlhaniHMA review of candidate therapies for Middle East respiratory" exact="syndrome" post="from a molecular perspectiveJ Med Microbiol20176691261127428855003 53.Al-TawfiqJAMemishZAUpdate on therapeutic"/>
 <result pre="perspectiveJ Med Microbiol20176691261127428855003 53.Al-TawfiqJAMemishZAUpdate on therapeutic options for Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV)Expert Rev Anti-Infect Ther201715326927527937060 54.Zhang C, Huang"/>
 <result pre="Med Microbiol20176691261127428855003 53.Al-TawfiqJAMemishZAUpdate on therapeutic options for Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV)Expert Rev Anti-Infect Ther201715326927527937060 54.Zhang C, Huang S,"/>
 <result pre="as a broad-spectrum antiviral: an updateAntivir Res2014107849424769245 57.AbdelnabiRNeytsJDelangLTowards antivirals against" exact="chikungunya" post="virusAntivir Res2015121596826119058 58.TeissierEPeninFPÃ©cheurEITargeting cell entry of enveloped viruses as"/>
 <result pre="Arbidol combined with LPV/r versus LPV/r alone against corona virus" exact="disease" post="2019: a retrospective cohort study. J Inf Secur 2020."/>
 <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirus. J Biol Chem 2020. 61.Tchesnokov EP; Feng"/>
 <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirus. J Biol Chem 2020. 61.Tchesnokov EP; Feng JY;"/>
 <result pre="Natl Acad Sci U S A201811545116131161830352857 69.FurutaYGowenBBTakahashiKShirakiKSmeeDFBarnardDLFavipiravir (T-705), a novel" exact="viral" post="RNA polymerase inhibitorAntivir Res2013100244645424084488 70.FurutaYKomenoTNakamuraTFavipiravir (T-705), a broad spectrum"/>
 <result pre="polymerase inhibitorAntivir Res2013100244645424084488 70.FurutaYKomenoTNakamuraTFavipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc Jpn Acad Ser B Phys Biol Sci201793744946328769016"/>
 <result pre="and emerging RNA virusesAntivir Res2018153859429524445 73.DongLHuSGaoJDiscovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discov Ther2020141586032147628 74.PotardVCanestriAGallienSCostagliolaDUse of darunavir in HIV-1-infected"/>
 <result pre="J. M., Development of darunavir over the entire spectrum of" exact="HIV infection." post="Enferm Infecc Microbiol Clin 2018, 36 Suppl 2, 3â€&quot;9."/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020."/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. 86.GaoJTianZYangXBreakthrough:"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. 86.GaoJTianZYangXBreakthrough: chloroquine"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends2020141727332074550 87.Expert consensus on chloroquine phosphate"/>
 <result pre="and research information on drug-induced liver injury, National Institute of" exact="Diabetes" post="and Digestive and Kidney Diseases: Bethesda (MD), 2012. 90.HuCLuLWanJPWenCThe"/>
 <result pre="drug-induced liver injury, National Institute of Diabetes and Digestive and" exact="Kidney" post="Diseases: Bethesda (MD), 2012. 90.HuCLuLWanJPWenCThe pharmacological mechanisms and therapeutic"/>
 <result pre="2012. 90.HuCLuLWanJPWenCThe pharmacological mechanisms and therapeutic activities of hydroxychloroquine in" exact="rheumatic" post="and related diseasesCurr Med Chem201724202241224928302011 91.SchrezenmeierEDÃ¶rnerTMechanisms of action of"/>
 <result pre="new relevanceCleve Clin J Med201885645946729883308 94.KhaliliHDastanFDehghan ManshadiSAA case report of" exact="hearing loss" post="post use of hydroxychloroquine in a HIV-infected patientDaru20142212024450358 95.CaoBParnellLADiamondMSMysorekarIUInhibition"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov202061632194981 99.Sahraei Z; Shabani M; Shokouhi S;"/>
 <result pre="Z; Shabani M; Shokouhi S; Saffaei A, Aminoquinolines against coronavirus" exact="disease" post="2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents"/>
 <result pre="Int J Antimicrob Agents 2020, 105945. 100.SnellLMMcGahaTLBrooksDGType I interferon in" exact="chronic" post="virus infection and cancerTrends Immunol201738854255728579323 101.Sen N; Sung P;"/>
 <result pre="J Antimicrob Agents 2020, 105945. 100.SnellLMMcGahaTLBrooksDGType I interferon in chronic" exact="virus infection" post="and cancerTrends Immunol201738854255728579323 101.Sen N; Sung P; Panda A;"/>
 <result pre="Antimicrob Agents 2020, 105945. 100.SnellLMMcGahaTLBrooksDGType I interferon in chronic virus" exact="infection" post="and cancerTrends Immunol201738854255728579323 101.Sen N; Sung P; Panda A;"/>
 <result pre="N; Sung P; Panda A; Arvin AM, Distinctive roles for" exact="type I" post="and type II interferons and interferon regulatory factors in"/>
 <result pre="Panda A; Arvin AM, Distinctive roles for type I and" exact="type II" post="interferons and interferon regulatory factors in the host cell"/>
 <result pre="and cyclosporine treatment separately and in combination on Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) replication in a human in-vitro and"/>
 <result pre="cyclosporine treatment separately and in combination on Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo"/>
 <result pre="against Zika virusJ Med Virol201890181228851097 104.SanmartÃ­RRuiz-EsquideVBastidaCSoyDTocilizumab in the treatment of" exact="adult" post="rheumatoid arthritisImmunotherapy201810644746429495891 105.AhnSSJungSMSongJJParkYBParkJYLeeSWSafety of tocilizumab in rheumatoid arthritis patients"/>
 <result pre="the treatment of adult rheumatoid arthritisImmunotherapy201810644746429495891 105.AhnSSJungSMSongJJParkYBParkJYLeeSWSafety of tocilizumab in" exact="rheumatoid arthritis" post="patients with resolved hepatitis B virus infection: data from"/>
 <result pre="treatment of adult rheumatoid arthritisImmunotherapy201810644746429495891 105.AhnSSJungSMSongJJParkYBParkJYLeeSWSafety of tocilizumab in rheumatoid" exact="arthritis" post="patients with resolved hepatitis B virus infection: data from"/>
 <result pre="arthritisImmunotherapy201810644746429495891 105.AhnSSJungSMSongJJParkYBParkJYLeeSWSafety of tocilizumab in rheumatoid arthritis patients with resolved" exact="hepatitis" post="B virus infection: data from real-world experienceYonsei Med J201859345245629611409"/>
 <result pre="Z, Cardiovascular implications of fatal outcomes of patients with coronavirus" exact="disease" post="2019 (COVID-19). JAMA Cardiol 2020. 114.Hu H; Ma F;"/>
 <result pre="114.Hu H; Ma F; Wei X; Fang Y, Coronavirus fulminant" exact="myocarditis" post="saved with glucocorticoid and human immunoglobulin. Eur Heart J"/>
 <result pre="Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur" exact="Heart" post="J 2020. 115.Zhang B; Liu S; Tan T; Huang"/>
</results>
